Potassium-Competitive Acid Blockers: New Opportunities of Antisecretory Therapy in Gastroesophageal Reflux Disease

Aim: to present modern data on the efficacy and safety of using potassium-competitive acid blockers (P-CAB) using tegoprazan as an example in patients with gastroesophageal reflux disease. Key points. Potassium-competitive blockers of hydrochloric acid secretion, according to clinical studies, have demonstrated high clinical efficacy and safety in patients with gastroesophageal reflux disease. The advantages of this class of drugs include a faster and longer-lasting antisecretory effect, which does not depend on food intake, as well as the absence of the influence of genetic polymorphisms of the CYP2C19 isoenzyme on pharmacokinetics and the risk of drug interactions. In patients with nocturnal heartburn, the potassium-competitive acid blocker tegoprazan may be the drug of choice to achieve a faster and longer-lasting clinical effect and improve sleep quality. Tegoprazan is effective against nocturnal acid breakthroughs. In several studies, tegoprazan was superior to placebo and proton pump inhibitors (PPIs) in eliminating major symptoms in patients with nonerosive reflux disease and to PPIs in treating erosive esophagitis. P-CABs are considered the drugs of choice in the treatment of gastroesophageal reflux disease refractory to PPIs. Conclusion. Further studies are needed, including in the Russian Federation, to confirm the high efficacy and safety of tegoprazan.